Social impact of the burden of psoriasis: Effects on patients and practice

Dermatology Online Journal

Volumn 20, Issue 8, 2014, Pages

  Feldman, Steven R ^a   Malakouti, Mona ^b   Koo, John Y M ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burden; Healthcare reform; Patient; Physician; Psoriasis; Treatment

Indexed keywords

ADALIMUMAB; BRODALUMAB; ETANERCEPT; INFLIXIMAB; IXEKIZUMAB; SECUKINUMAB; USTEKINUMAB;

CLINICAL PRACTICE; EMOTIONAL STRESS; FEAR; GUILT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOLISTIC CARE; HUMAN; HUMAN RELATION; INTIMACY; OCCUPATION; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PATIENT SATISFACTION; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SELF CONCEPT; SELF ESTEEM; SEXUAL FUNCTION; SHAME; SOCIAL ASPECT; SOCIAL DISCRIMINATION; SOCIAL REJECTION; SOCIAL STIGMA; TREATMENT OUTCOME; PSYCHOLOGY; SOCIAL DESIRABILITY;

HUMANS; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; SOCIAL DESIRABILITY;

EID: 84906278947     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol. 2013;44:82-90. [PMID:23796812]
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. [PMID:19641206]
3. Ahmed A, Leon A, Butler DC, Reichenberg J. Quality-of-life effects of common dermatological diseases. Semin Cutan Med Surg. 2013;32(2):101-9. [PMID:24049968]
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-7. [PMID:10459113]
5. Bhutani T, Patel T, Koo B, Nguyen T, Hong J, Koo J. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. J Am Acad Dermatol. 2013;69(2):e79-88. [PMID:23207011]
6. Feldman S, Behnam SM, Behnam SE, Koo JY. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol. 2005;53(1 Suppl 1)S78-85. [PMID:15968267]
7. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-92. [PMID:16343026]
8. Kennedy DM, Caselli RJ, Berry LL. A roadmap for improving healthcare service quality. J Healthc Manag. 2011;56(6):385-400. [PMID:22201201]
9. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152(5):954-60. [PMID:15888152]
10. Guenther L, Han C, Szapary P, Schenkel B, Poulin Y, Bourcier M, Ortonne JP, Sofen HL. Impact of ustekinumab on healthrelated quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. J Eur Acad Dermatol Venereol. 2011;25(7):851-7. [PMID:21521375]
11. Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012;92(1):67-72. [PMID:21879243]
12. Gupta MA, Gupta AK, Watteel GN. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis. 1998;61(6):339-42. [PMID:9640555]
13. Young M. The psychological and social burdens of psoriasis. Dermatol Nurs. 2005;17(1):15-9. [PMID:15782923]
14. Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol. 1993;32(8):587-91. [PMID:8407075]
15. Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof P.C, van Rossum MM. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164(6):1247-55. [PMID:21332459]
16. Magin P, Heading G, Adams J, Pond D. Sex and the skin: a qualitative study of patients with acne, psoriasis and atopic eczema. Psychol Health Med. 2010;15(4):454-62. [PMID:20677083]
17. Splete H. Impact of psoriasis on sexual activity. Skin & Allergy News. 2013. Available at: http://www.skinandallergynews.com/index.php?id=159&tx_ttnews%5Btt_news%5D=223073&cHash=5d1771b5739545e6e7 17000274d012d0. Accessed January 30, 2014.
18. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236-44. [PMID:7888360]
19. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-4. [PMID:11255325]
20. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24-8. [PMID:16467020]
21. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102-10. [PMID:16902286]
22. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57(6):963-71. [PMID:17761358]
23. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21(1):54-9. [PMID:18318886]
24. Heller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Menter A, Koo JY. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin. 2012;30(2):281-91. [PMID:22284142]
25. Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2013 doi: 10.1111/j.365-4632.2012.05798.x. [Epub ahead of print]. [PMID:23557000]
26. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53(1):101-7. [PMID:15965429]
27. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153(6):1192-9. [PMID:16307657]
28. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161-8. [PMID:16704649]
29. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341-50. [PMID:18058494]
30. Reich K, Segaert S, van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239-49. [PMID:19752505]
31. Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A, Japanese Ustekinumab Study G. Impact of ustekinumab on healthrelated quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2/3 trial. J Dermatol. 2012;39(9):761-9. [PMID:22409383]
32. Gisondi P, Girolomoni G. Impact of TNF-α antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol. 2013;148(3):243-8. [PMID:23670060]
33. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB, Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457-65. [PMID:20462664]
34. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011;22(6):337-47. [PMID:21034290]
35. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62(5):812-18. [PMID:20219265]
36. Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67-76. [PMID:21616560]
37. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-9. [PMID:22455413]
38. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-9. [PMID:22455412]
39. Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014;170(3):705-15. [PMID:24079852]
40. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-21. [PMID:23106107]
41. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M,Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-11. [PMID:23362969]
42. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-5. [PMID:23945732]
43. Bewley A, Burrage DM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol. 2014;28(6):763-70. [PMID:23663069]
44. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398-405. [PMID:23565643]
45. Clayton A, Ramamurthy S. The impact of physical illness on sexual dysfunction. Adv Psychosom Med. 2008;2970-88. [PMID:18391558]
46. Atkinson JG, Masiulis KE, Felgner L, Schumacher DN. Provider-initiated pay-for-performance in a clinically integrated hospital network. J Healthc Qual. 2010;32(1):42-50. [PMID:20151591]
47. Press I, Fullam F. Patient satisfaction in pay for performance programs. Qual Manag Health Care. 2011;20(2):110-5. [PMID:21467898]
48. Riskind P, Fossey L, Brill K. Why measure patient satisfaction? J Med Pract Manage. 2011;26(4):217-20. [PMID:21506460]
49. Shirley ED, Sanders JO. Patient satisfaction: Implications and predictors of success. J Bone Joint Surg Am. 2013;95(10):e69. [PMID:23677370]
50. CAHPS®: Consumer Assessment of Healthcare Providers and Systems. Agency for Healthcare Research and Quality. 2013. Available at: https://cahps.ahrq.gov/. Accessed March 10, 2014.
51. Medicare.gov. Hospital Compare. Centers for Medicare & Medicaid Services. Available at: www.medicare.gov/hospitalcompare. Accessed March 10, 2014.
52. CAHPS® Survey for Accountable Care Organizations Participating in Medicare Initiatives. Centers for Medicare & Medicaid Services, Baltimore, MD. Available at: http://acocahps.cms.gov.Accessed March 10, 2014.
53. Physician quality measure reporting. American Medical Associatio n. Available at: http://www.ama-assn.org/ama/pub/physician-resources/clinical-practice-improvement/clinical-quality/physician-quality-reporting-system.page. Accessed March 10, 2014.
54. Medicare.gov. Physician Compare. Centers for Medicare & Medicaid Services. Available at: www.medicare.gov/physiciancompare. Accessed March 10, 2014.